Ronald C Chen
Overview
Explore the profile of Ronald C Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
268
Citations
4191
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asiri I, Chen R, Master V, Mi L, James S, Odedina F, et al.
Cancer Epidemiol
. 2025 Feb;
95:102769.
PMID: 39947118
Background And Aims: Enzalutamide (ENZ) and Abiraterone Acetate (AA) are both first-line treatments for castration-resistant prostate cancer (CRPC). CRPC patients may switch from ENZ to AA or from AA to...
2.
Chen R, Fuldeore R, Greatsinger A, Hepp Z, Liu Q, Wright P, et al.
Urol Oncol
. 2024 Dec;
43(3):189.e9-189.e18.
PMID: 39675951
Background: Given the changing treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC), this study aimed to describe real-world treatments, overall survival (OS), health care resource utilization (HCRU), and...
3.
Shinde N, Zhu Y, Wang W, Li W, Lin Y, Gan G, et al.
ArXiv
. 2024 Dec;
PMID: 39650603
Objective: Proton spot-scanning arc therapy (ARC) is an emerging modality that can improve the high-dose conformity to targets compared with standard intensity-modulated proton therapy (IMPT). However, the efficient treatment delivery...
4.
Ma C, Adler R, Neidre D, Chen R, Northouse L, Rini C, et al.
J Med Internet Res
. 2024 Dec;
26:e51877.
PMID: 39625741
Background: Family-based randomized controlled trials (RCTs) encounter recruitment and retention challenges. Cancer-focused RCTs typically recruit convenience samples from local cancer centers and hospitals. Objective: This study aimed to examine the...
5.
Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, et al.
Bladder Cancer
. 2024 Nov;
10(3):199-213.
PMID: 39493817
Background: Trimodality therapy (TMT) is a viable option for muscle-invasive localized bladder cancer, providing an alternative to radical cystectomy in properly selected patients. The approval of novel therapeutics in different...
6.
Rock C, Kane K, Sood S, Cao Y, Chen R, Wang F
Adv Radiat Oncol
. 2024 Oct;
9(12):101626.
PMID: 39474010
Purpose: There is very little information detailing outcomes and toxicity following reirradiation for ultracentrally located thoracic tumors, and detailed dosimetric data are nonexistent. These data are critical for the safe...
7.
Gaylis F, Leapman M, Ellis S, Hu S, Cooperberg M, Loeb S, et al.
Urol Pract
. 2024 Oct;
12(2):241-248.
PMID: 39453985
Introduction: Practice-level strategies to improve the use of conservative management for low-risk prostate cancer have not been rigorously evaluated. We examined the feasibility of implementation and preliminary outcomes of a...
8.
Zhu Y, Zhang W, Setianegara J, Lin Y, Traneus E, Long Y, et al.
Phys Med Biol
. 2024 Oct;
69(21).
PMID: 39419102
LATTICE, a spatially fractionated radiation therapy (SFRT) modality, is a 3D generalization of GRID and delivers highly modulated peak-valley spatial dose distribution to tumor targets, characterized by peak-to-valley dose ratio...
9.
Chen R, Basak R, Dusetzina S, Usinger D, Mohammed Z, Falchook A, et al.
JNCI Cancer Spectr
. 2024 Oct;
8(6).
PMID: 39383199
Background: Posttreatment surveillance affects millions of cancer survivors, but empiric data to guide clinical practice are lacking. This study assessed whether the intensity of surveillance testing after radical prostatectomy or...
10.
Wang C, Lin B, Lin Y, Shontz S, Huang W, Chen R, et al.
Med Phys
. 2024 Aug;
51(10):7067-7079.
PMID: 39140647
Background: Proton therapy is preferred for its dose conformality to spare normal tissues and organs-at-risk (OAR) via Bragg peaks with negligible exit dose. However, proton dose conformality can be further...